BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?